The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial
Open accessAbstract
Importance: Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic drugs provides clinical benefit to patients with advanced or metastatic colorectal cancer, but the optimal choice of the initial biologic therapy in previously untreated patients is unknown. Objective: To determine if the addition of cetuximab vs bevacizumab to the combination of leucovorin, fluorouracil, and oxaliplatin (mFOLFOX6) regimen or the combination of leucovorin, fluorouracil, and irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-type (wt) colorectal cancer. Design, Setting, and Participants: Patients (≥18 years) enrolled at community and academic centers throughout the National Clinical Trials Network in the United States and Canada (November 2005-March 2012) with previously untreated advanced or metastatic colorectal cancer whose tumors were KRAS wt chose to take either the mFOLFOX6 regimen or the FOLFIRI regimen as chemotherapy and were randomized to receive either cetuximab (n = 578) or bevacizumab (n = 559). The last date of follow-up was December 15, 2015. Interventions: Cetuximab vs bevacizumab combined with either mFOLFOX6 or FOLFIRI chemotherapy regimen chosen by the treating physician and patient. Main Outcomes and Measures: The primary end point was overall survival. Secondary objectives included progression-free survival and overall response rate, site-reported confirmed or unconfirmed complete or partial response. Results: Among 1137 patients (median age, 59 years; 440 [39%] women), 1074 (94%) of patients met eligibility criteria. As of December 15, 2015, median follow-up for 263 surviving patients was 47.4 months (range, 0-110.7 months), and 82% of patients (938 of 1137) experienced disease progression. The median overall survival was 30.0 months in the cetuximab-chemotherapy group and 29.0 months in the bevacizumab-chemotherapy group with a stratified hazard ratio (HR) of 0.88 (95% CI, 0.77-1.01; P = .08). The median progression-free survival was 10.5 months in the cetuximab-chemotherapy group and 10.6 months in the bevacizumab-chemotherapy group with a stratified HR of 0.95 (95% CI, 0.84-1.08; P = .45). Response rates were not significantly different, 59.6% vs 55.2% for cetuximab and bevacizumab, respectively (difference, 4.4%, 95% CI, 1.0%-9.0%, P = .13). Conclusions and Relevance: Among patients with KRAS wt untreated advanced or metastatic colorectal cancer, there was no significant difference in overall survival between the addition of cetuximab vs bevacizumab to chemotherapy as initial biologic treatment. Trial Registration: clinicaltrials.gov identifier: NCT00265850.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, patients with metastatic colorectal cancer and related intestinal malignancies tend to receive similar treatments and live for many months with relatively stable health (median overall survival >2 years) [44], facilitating study completion and potentially derivation of durable benefit from the intervention.”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although a higher percentage of men enrolled compared to most prior mindfulness interventions for integrative cancer care [34], the evaluable study sample included a greater proportion of younger (age <50), female, White and Latino or Hispanic patients relative to the underlying population [44, 53].”
From Being present: A single-arm feasibility study of audio-based mindfulness meditation for colorectal cancer patients and caregivers (2018) · cites this paper as [44]
Experimental — accuracy not yet measuredIn the citing paper
“This trial demonstrated that patients in the cetuximab plus chemotherapy group had slightly higher overall survival versus patients in the bevacizumab plus chemotherapy group (30.0 months versus 29.0 months).”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similar to the FIRE-3 trial, median progression-free survival and response rates were similar between groups.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [65]
In the citing paper
“Similarly, the CALGB/SWOG 80405 trial showed that both cetuximab and bevacizumab provided comparable outcomes when combined with chemotherapy in the overall population, but the benefit of anti-EGFR therapy was again limited to RAS wild-type tumors [21].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [21]
In the citing paper
“however, it must be noted here that this pooled analysis also included patients who had received a nonstandard treatment regimen, including FUFIRI, FUFOX, and mIROX as induction chemotherapies and bevacizumab monotherapy or observation alone as maintenance therapies in clinical trials [22,23].”
From The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“dence indicated that cetuximab activity was unrelated to tumor expression of EGFR.(8) Bevacizumab, a humanized”
BackgroundThe consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“a The 0-to-5 coded scale describing patient daily level of functioning from fully active (0) to completely disabled (4); dead (5).”
BackgroundDouillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 4×
“Results are reported for (1) the primary 2-group comparison between cetuximab and bevacizumab; (2) the comparison of cetuximab vs bevacizumab in an expanded RAS subset described above; and (3) the chemotherapy subgroups.”
MethodInfluentialSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 900
Innocenti, F., Mu, W., Qu, X., Ou, F., Kabbarah, O., Blanke, C. D., Venook, A. P., Lenz, H., & Rashid, N. U. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00825 · Cited by 15
Self-citationPlant-based diet and survival among patients with metastatic colorectal cancer
Cheng, E., Ou, F., Gatten, C. A., Ma, C., Venook, A. P., Lenz, H., O'Reilly, E. M., Campbell, P. T., Kuang, C., Caan, B. J., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae213 · Cited by 16
Self-citationCost-effectiveness analysis of laparoscopic versus open surgery in colon cancer
Mar, J., Antón-Ladislao, A., Ibarrondo, O., Arrospide, A., Lázaro, S., González, N., Baré, M., Callejo, D., Redondo, M., Quintana, J. M., et al. (2018) · Surgical Endoscopy · doi:10.1007/s00464-018-6250-9 · Cited by 15
Salem, M. E., Yin, J., Weinberg, B. A., Renfro, L. A., Pederson, L., Maughan, T., Adams, R., Cutsem, E. V., Falcone, A., Tebbutt, N. C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.020 · Cited by 15
Hernia and Cancer: The Points Where the Roads Intersect
Kulaçoğlu, H., & Köckerling, F. (2019) · Frontiers in Surgery · doi:10.3389/fsurg.2019.00019 · Cited by 15
Liu, Y., Huang, J., Guo, C., Yang, S., Ye, L., Wu, S., Zhang, X.-F., Yang, X., Han, C., Pei, Q., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-04014-x · Cited by 15
Palazzolo, G., Mollica, H., Lusi, V., Rutigliani, M., Francesco, M. D., Pereira, R. C., Filauro, M., Paleari, L., DeCensi, A., & Decuzzi, P. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100760 · Cited by 15
Influence of primary tumor location and resection on survival in metastatic colorectal cancer
Tharin, Z., Blanc, J., Alaoui, I. C., Bertaut, A., & Ghiringhelli, F. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i11.1296 · Cited by 15
Bai, M., Li, Z., & Ba, Y. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s300968 · Cited by 13
Han, Z., Zhang, C., Wang, Q., Li, L., Wang, M., Li, X., & Yang, C. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211012666 · Cited by 15
RetractedChiu, K. W.-H., Lam, K. O., An, H., Cheung, G. T. C., Lau, J. K.-S., Choy, T., & Lee, V. H.-F. (2018) · BMC Cancer · doi:10.1186/s12885-018-4687-9 · Cited by 15
Péron, J., Mercier, F., Tuech, J., Younan, R. J., Sidéris, L., Gelli, M., Dumont, F., Roy, B. L., Sgarbura, O. A., Dico, R. L., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.07.027 · Cited by 15
Vitamin D supplementation: a potential therapeutic agent for metastatic colorectal cancer
Yuan, C., & Ng, K. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0958-8 · Cited by 15
Snyder, R. A., He, J., Le‐Rademacher, J. G., Ou, F., Dodge, A., Zemla, T., Paskett, E. D., Chang, G. J., Innocenti, F., Blanke, C. D., et al. (2021) · Cancer · doi:10.1002/cncr.33649 · Cited by 15
Self-citationEarly-Onset Colorectal Cancer: From Genetic Discovery to Clinical Innovation
Turk, A. A., Mondaca, S., Nervi, B., Morris, A. D., Finer, Z. R., & Holowatyj, A. N. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473618 · Cited by 18
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer
Gootjes, E. C., Bakkerus, L., Adhin, A. A., Zonderhuis, B. M., Versteeg, K. S., Tuynman, J. B., Meijerink, M. R., Haasbeek, C. J. A., de Wilt, J. H. W., Grünhagen, D. J., et al. (2026) · JAMA · doi:10.1001/jama.2026.1929 · Cited by 14
He, J., Liu, Y., Liu, C., Hu, H., Sun, L., Xu, D., Li, J., Wang, J., Chen, X., Lin, R., et al. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231152350 · Cited by 14
Allan, Z., Liu, D. S., Lee, M., Tie, J., & Clemons, N. J. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvad188 · Cited by 14
Jabbour, S. K., Kumar, R. N., Anderson, B. M., Chino, J., Jethwa, K. R., McDowell, L. J., Lo, A., Owen, D., Pollom, E. L., Tree, A. C., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.01.010 · Cited by 14
Li, C., Jia, H., Wei, X., Xue, G., Xu, J., Cheng, R., Cheng, Y., Song, Q., Shen, Z., & Xue, C. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.3c05511 · Cited by 14
Ma, L., Ai, F., Xiao, H., Wang, F., Shi, L., Bai, X., Zhu, Y., & Ma, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1367747 · Cited by 16
Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis
Ridouane, Y., Lopes, G. D. L., Jr., Ku, G. Y., Masud, H., & Haaland, B. A. (2017) · Oncotarget · doi:10.18632/oncotarget.20185 · Cited by 13
“CALGB-SWOG 80405 [15] Chemotherapyb + cetuximab (578) 0.”
Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?
Eisterer, W., & Prager, G. W. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02278-7 · Cited by 15
Yaeger, R. D., Paroder, V., Bates, . D. B., Capanu, M., Chou, J. F., Tang, L. A., Chatila, W. K., Schultz, N. D., Hersch, J., & Kelsen, D. P. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.02.008 · Cited by 14
Tsai, H.-L., Chen, Y.-C., Yin, T.-C., Su, W.-C., Chen, P.-J., Chang, T.-K., Li, C.-C., Huang, C.-W., & Wang, J.-Y. (2022) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504022x16451187313084 · Cited by 13
Yao, L., Zao, X.-L., Pan, X.-F., Zhang, H.-G., Wang, F.-J., & Qiao, P.-F. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2045827 · Cited by 13
McCoy, M., Wolf, S., Struck, V., Thomas, N., Husmann, G., Zeuzem, S., Koch, C., Trojan, J., Schnitzbauer, A. A., Bechstein, W. O., et al. (2022) · Cancers · doi:10.3390/cancers14071641 · Cited by 14
“Thus, monoclonal anti-EGFR antibodies cetuximab and panitumumab can be utilized to inhibit MAPK downstream signalling and are approved for treatment in combination with or after conventional chemotherapy [9–12].”
Zwart, K., van der Baan, F. H., Cohen, R., Aparicio, T., de la Fouchardière, C., Lecomte, T., Punt, C. J. A., Sefrioui, D., Verheijden, R. J., Vink, G. R., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.6223 · Cited by 13
Suenaga, M., Stintzing, S., Cao, S., Zhang, W., Yang, D., Ning, Y., Okazaki, S., Berger, M. D., Miyamoto, Y., Schirripa, M., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.019 · Cited by 14
Self-citationBody Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405
Guercio, B. J., Zhang, S., Venook, A. P., Ou, F., Niedzwiecki, D., Lenz, H., Innocenti, F., Mullen, B. C., O’Neil, B. H., Shaw, J. E., et al. (2020) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkaa024 · Cited by 15
“(20), our covariate analysis supplemented this data with KRAS data from the Alliance A151425 Project (a collaboration with Genentech) (22) and Merck BEAMing tech-”
MethodSelf-citationPrimary tumor location and survival in colorectal cancer: A retrospective cohort study
Aggarwal, H., Sheffield, K. M., Li, L., Lenis, D., Sorg, R. A., Barzi, A., & Miksad, R. A. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i4.405 · Cited by 14
Kim, S., Kim, J., Suh, K. J., Chang, W., Kim, J. W., Oh, H., Cho, J. Y., Kim, J. H., Cho, S., Kim, J. H., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03233-7 · Cited by 14
Conti, V., Bellis, E. D., Manzo, V., Sabbatino, F., Iannello, F., Piaz, F. D., Izzo, V., Charlier, B., Stefanelli, B., Torsiello, M., et al. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030113 · Cited by 14
“They are commonly used to treat solid cancer types such as gastrointestinal, head-neck and breast cancers associated or not to other chemotherapeutics and both cytotoxic and biologic drugs [1,2].”
BackgroundWang, R., Fang, P., Chen, X., Ji, J., Yu, D., Mei, F., Wang, Z., Zhou, W., Peng, W., Wang, R., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102213 · Cited by 14
“58–60 This strategy is particularly relevant for the CMS4 subtype, which is associated with poor prognosis and resistance to standard therapies.”
Nakamura, Y., Yamashita, R., Okamoto, W., Komatsu, Y., Yuki, S., Ueno, M., Kato, K., Taniguchi, H., Kagawa, Y., Denda, T., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00653 · Cited by 13
Kumar, S., Gahramanov, V., Patel, S. H., Yaglom, J. A., Kaczmarczyk, L. S., Alexandrov, I. A., Gerlitz, G., Salmon‐Divon, M., & Sherman, M. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108717 · Cited by 13
Titin as a potential novel therapeutic target in colorectal cancer
Wei, H., Ren, K., Zhang, Q., Jin, Y., Cao, B., Tian, Z., Mao, T., & Ren, L. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17866 · Cited by 13
Progress of research on molecular targeted therapies for colorectal cancer
Huang, S., Ye, J., Gao, X., Huang, X., Huang, J., Lu, L., Lu, C., Li, Y., Luo, M., Xie, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1160949 · Cited by 13
“Moreover, previous studies have shown that cetuximab was as effective as bevacizumab in patients with RAS WT (Heinemann et al., 2014; Venook et al., 2017).”
BackgroundResultMechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics
Parseghian, C. M., Eluri, M., Kopetz, S., & Raghav, K. P. S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1176657 · Cited by 16
“With the recent impetus on moving the anti-EGFR therapy to the upfront setting, especially in RAS/BRAF-WT left-sided mCRC (Venook et al., 2017), data emerging from resistance in the first line setting in combination with cytotoxic chemotherapy is fast emerging and sketching a vastly different profile.”
BackgroundMatikas, A., Souglakos, J., Katsaounis, P., Kotsakis, A. P., Kouroupakis, P., Pantazopoulos, N., Kentepozidis, N. K., Nikolaidi, A., Messaritakis, I., Tzovara, I., et al. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00647-3 · Cited by 13
Xin, M., Xie, Q., Ma, L., An, G., Xiao, J., Li, J., Liu, X., Gao, P., Liang, J., & Li, Y. (2019) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000817 · Cited by 13
Real-World Use of Trifluridine/Tipiracil for Patients with Metastatic Colorectal Cancer in Canada
Samawi, H. H., Brezden‐Masley, C., Afzal, A. R., Cheung, W. Y., & Dolley, A. (2019) · Current Oncology · doi:10.3747/co.26.5107 · Cited by 14
Bao, Y., Hu, Q., Wang, X., Feng, X., He, Y. G., Guo, Y., & Fu, D. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110377 · Cited by 13
Safety and efficacy of nintedanib for the treatment of metastatic colorectal cancer
Martínez, M. C. R., Sánchez, A., & García‐Carbonero, R. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1385762 · Cited by 14
Hsu, H., Liu, Y., Wang, C., Chou, W., Hsu, Y., Chiang, J., Lin, Y., & Yang, T. (2019) · Cancer Medicine · doi:10.1002/cam4.2235 · Cited by 13
Germani, M. M., Borelli, B., Hashimoto, T., Nakamura, Y., Oldani, S., Battaglin, F., Bergamo, F., Salvatore, L., Stahler, A., Antoniotti, C., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01003 · Cited by 12
Self-citationLee, S. F., Choi, C., Chan, S. K., Lam, K. O., Lee, V. H.-F., Wong, I. O.-L., & Chiang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651299 · Cited by 12
“The CALGB 80405 trial, which is the largest one, has demonstrated equivalence of antiEGFR mAb and bevacizumab in terms progression-free survival (PFS) and overall survival (OS) (5).”
BackgroundMethodLiu, H., Liu, H., Zhou, Z., Chung, J., Zhang, G., Chang, J., Parise, R. A., Chu, E., & Schmitz, J. C. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01156-7 · Cited by 12
Heinrich, K., Karthaus, M., Fruehauf, S., Graeven, U., Mueller, L., König, A. O., von Weikersthal, L. F., Caca, K., Kretzschmar, A., Goekkurt, E., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101568 · Cited by 14
Desette, A., Guichet, P., Emambux, S., Masliantsev, K., Cortes, U., Ndiaye, B., Milin, S., George, S., Faigner, M., Tisserand, J., et al. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.07.008 · Cited by 12
Wilson, B. E., Booth, C. M., Patel, S. V., Berry, S. R., Kong, W., & Merchant, S. J. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.12.003 · Cited by 14
Self-citationBani, N., Rahmani, F., Shakour, N., Amerizadeh, F., Khalili‐Tanha, G., Khazaei, M., Hassanian, S. M., Kerachian, M. A., Abbaszadegan, M. R., Mojarad, M., et al. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206296355240325113920 · Cited by 12
The changing face of treatment for metastatic colorectal cancer
Pfeiffer, P., Köhne, C.-H., & Qvortrup, C. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1543593 · Cited by 12
“CALGB 80,405 [32], doublet chemotherapy with cetuximab resulted in higher ORR but with no significant difference in PFS or OS.”
BackgroundFOLFOXIRI plus biologics in advanced colorectal cancer
Alfonso, P. G., Torres, G., García, G., Gallego, I., Ortega, L., Sandoval, C., Muñoz, A., & Vila, A. L. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1595580 · Cited by 12
Addeo, A., Weiss, G. J., & Gyawali, B. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.3684 · Cited by 12
Fiala, O., Ostašov, P., Hošek, P., Šorejs, O., Liška, V., Büchler, T., Poprach, A., Kučera, R., Topolčan, O., Šustr, J., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13761 · Cited by 12
Cetuximab versus bevacizumab in metastatic colorectal cancer: a comparative effectiveness study
Marques, R. P., Godinho, A. R., Heudtlass, P., Pais, H. L., Quintela, A., & Martins, A. P. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03167-0 · Cited by 12
Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center
Sharma, V., Sharma, A., Raina, V., Dabkara, D., Mohanti, B. K., Shukla, N. K., Pathy, S., Thulkar, S. P., Deo, S. V. S., Kumar, S., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08398-z · Cited by 12
“6 months) was remarkably different respectively [32].”
Iwasa, S., Muro, K., Morita, S., Park, Y. S., Nakamura, M., Kotaka, M., Nishina, T., Matsuoka, H., Ahn, J. B., Lee, K., et al. (2021) · Cancer Science · doi:10.1111/cas.15092 · Cited by 13
Zhang, H., You, J., Liu, W. Y., Chen, D., Zhang, S., & Wang, X. (2021) · Medicine · doi:10.1097/md.0000000000026714 · Cited by 12
Kimura, K., Fujioka, T., Mori, M., Adachi, T., Hiraishi, T., Hada, H., Ishikawa, T., & Tateishi, U. (2022) · Tomography · doi:10.3390/tomography8020088 · Cited by 12
Narita, Y., Yoshimoto, T., Namai, T., Asakawa, T., Kawakami, S., Gower‐Page, C., Reyes‐Rivera, I., Patel, A., & Nakamura, Y. (2022) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00022 · Cited by 12
Khalil, K., Musallam, H., Hassan, M., & Mahmoud, I. A. (2022) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2022.23.10.3421 · Cited by 12
“Also the integration of a targeted agent to doublet chemotherapy has increased response rates to around 60% (Venook et al, 2017).”
BackgroundPatkar, S., Chopde, A. N., Shetty, N., Kulkarni, S., Gala, K., Chandra, D., Ramaswamy, A., Ostwal, V., & Goel, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1073311 · Cited by 13
Ottaiano, A., Stefano, A. D., Capozzi, M., Nappi, A. G., Divitiis, C. D., Romano, C., Silvestro, L., Cassata, A., Casaretti, R., Tafuto, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00441 · Cited by 13
“…therapy or direct comparison between CT plus anti-EGFR vs. CT plus bevacizumab) (Maughan et al., 2011; Bokemeyer et al., 2012; Douillard et al., 2013; Schwartzberg et al., 2014; Passardi et al., 2015; Stintzing et al., 2016; Venook et al., 2017) including 3,805 patients KRAS or “RAS extended” wt.”
BackgroundMethodInfluentialReijonen, P., Osterlund, P. J., Isoniemi, H., Arola, J. T., & Nordin, A. J. (2018) · Scandinavian Journal of Surgery · doi:10.1177/1457496918812237 · Cited by 12
Palmieri, L., Fihri, A., Doat, S., Dubreuil, O., Manceau, G., Karoui, M., Wagner, M., Lucidarme, O., & Bachet, J. (2019) · European Radiology · doi:10.1007/s00330-018-5967-0 · Cited by 11
Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS
Margalit, O., Shacham‐Shmueli, E., Lawrence, Y. R., Yang, Y., Reiss, K. A., Golan, T., Mamtani, R., Halpern, N., Aderka, D., Giantonio, B. J., et al. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.06.001 · Cited by 12
Tharin, Z., Blanc, J., Alaoui, I. C., Bertaut, A., & Ghiringhelli, F. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-593 · Cited by 13
“It is now well established that primary tumor location (PTL) is a major prognostic factor in mCRC, right-sided mCRC’s having a poorer prognosis than left-sided mCRCs (13-15).”
BackgroundSynchronous liver metastases in patients with rectal cancer: can we establish which treatment first?
Pfeiffer, P., Gruenberger, T., & Glynne‐Jones, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918787993 · Cited by 12
“Bevacizumab or anti-EGFR in patients with RAS wild-type/BRAF wild-type metastatic colorectal cancer.[22-24]”
BackgroundBlood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies and Future Perspectives
Jacobsen, A., Siebler, J., Grützmann, R., Stürzl, M., & Naschberger, E. (2024) · Cancers · doi:10.3390/cancers16050890 · Cited by 11
“Venook et al. conducted a similar trial (CALGB/SWOG 80405) to test either FOLFIRI or FOLFOX plus cetuximab or bevacizumab and found no differences in OS, PFS and RR between bevacizumab and cetuximab [41].”
Suenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Dan, S., Seimiya, H., & Yamaguchi, K. (2020) · International Journal of Colorectal Disease · doi:10.1007/s00384-020-03748-y · Cited by 12
Froicu, E.-M., Oniciuc, O.-M., Afrăsânie, V.-A., Marinca, M. V., Riondino, S., Dumitrescu, E. A., Alexa‐Stratulat, T., Radu, I., Miron, L., Bacoanu, G., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14182074 · Cited by 14
“The median overall survival of patients with mCRC has exceeded 30 months with these novel treatments [2]; however, targeted therapies have unique toxicity profiles, including rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity.”
BackgroundKomorowski, A. S., MacKay, H. J., & Pezo, R. C. (2020) · Cancer Medicine · doi:10.1002/cam4.3095 · Cited by 11
Ottaiano, A., Scala, S., Santorsola, M., Trotta, A. M., D’Alterio, C., Portella, L., Clemente, O., Nappi, A. G., Zanaletti, N., Stefano, A. D., et al. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921989223 · Cited by 12
Hsu, H., Huang, K.-C., Chen, W.-S., Jiang, J., Yang, S.-H., Wang, H.-S., Chang, S., Lan, Y., Lin, C., Lin, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-94968-x · Cited by 11
VEGF and Immune Checkpoint Inhibition for Prevention of Brain Metastases
Mansouri, A., Padmanaban, V., Aregawi, D. G., & Glantz, M. (2021) · Neurology · doi:10.1212/wnl.0000000000012642 · Cited by 11
“Venook et al.(24) 2017 Colorectal 0/559 1/578 1,137 0.”
InfluentialKim, T. W., Taı̈eb, J., Gurary, E. B., Lerman, N., Cui, K. Y., & Yoshino, T. (2021) · Future Oncology · doi:10.2217/fon-2021-0899 · Cited by 11
Curcumin: A Novel Way to Improve Quality of Life for Colorectal Cancer Patients?
Layos, L., Martinez‐Balibrea, E., & de Porras, V. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214058 · Cited by 11
“Over the last ten years, new combinations of cytotoxic agents and targeted therapies have improved the prognosis of metastatic CRC (mCRC), and median overall survival is now 30 months, highlighting the importance of a “continuum of care” approach in advanced disease [3].”
BackgroundBevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
Dinu, I. M., Mihăilă, M., Diculescu, M., Croitoru, V. M., Turcu-Ştiolică, A., Bogdan, D., Miron, M. I., Lungulescu, C. V., Alexandrescu, S. T., Dumitraşcu, T., et al. (2023) · Medicina · doi:10.3390/medicina59020350 · Cited by 15
Devall, M. A. M., Ali, M. W., Eaton, S. D., Weisenberger, D. J., Reilley, M. J., Powell, S. M., Li, L., & Casey, G. (2023) · Cancer Medicine · doi:10.1002/cam4.6048 · Cited by 9
A review of targeted therapy and immune checkpoint inhibitors for metastatic colorectal cancer
Ruff, S. M., Brown, Z. J., & Pawlik, T. M. (2023) · Surgical Oncology · doi:10.1016/j.suronc.2023.101993 · Cited by 12
Nöpel‐Dünnebacke, S., Arnold, D., Hertel, J., Tannapfel, A., Hinke, A., Hegewisch‐Becker, S., & Reinacher‐Schick, A. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.007 · Cited by 11
EGFR antibodies in resectable metastatic colorectal liver metastasis: more harm than benefit?
Gholami, S., & Grothey, A. F. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30003-6 · Cited by 11
Palshof, J. A., Cederbye, C. N., Høgdall, E. V. S., Poulsen, T. S., Linnemann, D., Nygård, S. B., Stenvang, J., Christensen, I. J., Jensen, B. V., Pfeiffer, P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145027 · Cited by 11
Kuchel, A., Ahern, E. S., Collins, S., Whitehall, V., Okano, S., Pelecanos, A. M., Wyld, D., Eastgate, M. A., & Burge, M. (2020) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13420 · Cited by 11
Xu, K., He, J., Zhang, J., Liu, T., Yang, F., & Ren, T. (2020) · Bioscience Reports · doi:10.1042/bsr20201725 · Cited by 11
Wang, Z., Yao, Y.-C., Mai, Z.-J., Lin, W., Huang, Y., Jin, Y., Luo, H., Zhang, D., Wang, F., Wang, F., et al. (2021) · Engineering · doi:10.1016/j.eng.2020.10.017 · Cited by 11
Silva, V. S. E., Abdallah, E. A., Brito, A. B. C., Braun, A. C., Tariki, M. S., de Mello, C. A. L., Calsavara, V. F., Riechelmann, R. P., & Chinen, L. T. D. (2021) · Diagnostics · doi:10.3390/diagnostics11030502 · Cited by 11
Quintanilha, J. C. F., Wang, J., Sibley, A. B., Xu, W., Espin‐Garcia, O., Jiang, C., Etheridge, A. S., Ratain, M. J., Lenz, H., Bertagnolli, M. M., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33810 · Cited by 11
Self-citationColorectal cancer liver metastases: An update of treatment strategy and future perspectives
Hu, D., Pan, Y., & Chen, G. (2021) · Surgery in Practice and Science · doi:10.1016/j.sipas.2021.100042 · Cited by 11
Taniguchi, H., Uehara, K., Nakayama, G., Nakayama, H., Aiba, T., Hattori, N., Kataoka, M., Nakano, Y., Kawase, Y., Okochi, O., et al. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100786 · Cited by 12
Enzinger, A. C., Uno, H., McCleary, N. J., Frank, E., Sanoff, H. K., Loon, K. V., Matin, K., Bullock, A. J., Cronin, C. M., Bagley, J., et al. (2020) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2020.07.025 · Cited by 11
Self-citationBRAF Mutation in Colorectal Cancer: An Enigmatic Target
Eng, C. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03043 · Cited by 11
Alonso, V., Escudero, P., Fernández-Martos, C., Salud, A., Méndez, M., Gallego, J., Rodriguez, J.-R., Martín-Richard, M., Fernández-Plana, J., Manzano, H., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.05.004 · Cited by 10
Sütcüoğlu, O., Yıldırım, H. Ç., Almuradova, E., Günenç, D., & Yalçın, Ş. (2025) · Medicina · doi:10.3390/medicina61071202 · Cited by 10
“Similarly, the CALGB/SWOG 80405 trial showed that both cetuximab and bevacizumab provided comparable outcomes when combined with chemotherapy in the overall population, but the benefit of anti-EGFR therapy was again limited to RAS wild-type tumors [21].”
A comprehensive update on the potential of curcumin to enhance chemosensitivity in colorectal cancer
Shadnoush, M., Momenan, M., Seidel, V., Tierling, S., Fatemi, N., Mojarad, E. N., Norooz, M. T., & Cheraghpour, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00652-y · Cited by 11
“The median overall survival rate now reaches 30 months, underscoring the significance of a comprehensive and continuous approach to advanced disease management [7].”
Camera, S., Telli, T. A., Woff, E., Vandeputte, C., Kehagias, P., Guiot, T., Critchi, G., Wissam, Y., Bregni, G., Trevisi, E., et al. (2020) · Cancers · doi:10.3390/cancers12102752 · Cited by 10
“In recent clinical trials, the median overall survival (OS) of patients with unresectable disease has consistently reached the 30-month landmark [1,2].”
BackgroundMcCleary, N. J., Zhang, S., Ma, C., Ou, F., Bainter, T. M., Venook, A. P., Niedzwiecki, D., Lenz, H., Innocenti, F., O’Neil, B. H., et al. (2022) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2022.01.006 · Cited by 10
Self-citationFluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge
Vater, L. B., Lefebvre, B., Turk, A. A., & Clasen, S. C. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01256-6 · Cited by 11
Metadata
- Authors
- Venook, A. P., Niedzwiecki, D., Lenz, H.-J., Innocenti, F., Fruth, B., Meyerhardt, J. A., Schrag, D., Greene, C., O'Neil, B. H., Atkins, J. N., Berry, S., Polite, B. N., O'Reilly, E. M., Goldberg, R. M., Hochster, H. S., Schilsky, R. L., Bertagnolli, M. M., El-Khoueiry, A. B., Watson, P., Benson, A. B., Mulkerin, D. L., Mayer, R. J., & Blanke, C.
- Affiliations
- University of California, San Francisco (US)
- Duke University (US)
- University of Southern California (US)
- University of North Carolina at Chapel Hill (US)
- Mayo Clinic (US)
- Dana-Farber/Partners CancerCare, Boston, Massachusetts
- Indiana University, Simon Cancer Center, Indianapolis
- Southeastern Medical Oncology Center (US)
- Sunnybrook Health Science Centre (CA)
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois
- Memorial Sloan Kettering Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut
- American Society of Clinical Oncology (US)
- Brigham and Women's Hospital (US)
- Kinston Medical Specialists (US)
- Northwestern University (US)
- University of Wisconsin–Madison (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2017-06-20
- Volume
- 317
- Issue
- 23
- Pages
- 2392
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC5545896
- OpenAlex
- W2712978371
- Cited by
- 898
- References
- 24
- Citations by year
- 2026: 66 · 2025: 76 · 2024: 87 · 2023: 104 · 2022: 118 · 2021: 118 · 2020: 122 · 2019: 107 · 2018: 82 · 2017: 16
- FWCI
- 39.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Cancer Institute (U10CA180882, K05CA169384, U10CA180820, U10CA180791, U10CA180888, U10CA180836, U10CA180790, U10CA180830, U10CA180795, U10CA180850, R01CA149222, U10CA180838, U10CA180867, U10CA180821, U10CA180799)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Keywords
- metastatic colorectal cancer, KRAS wild-type, cetuximab, bevacizumab, first-line chemotherapy, mFOLFOX6, FOLFIRI, oxaliplatin, irinotecan, monoclonal antibodies, overall survival, progression-free survival, anti-EGFR therapy, anti-VEGF therapy, community oncology
- MeSH terms
- Bevacizumab, Cetuximab, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Canada, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Organoplatinum Compounds, Genes, ras, United States, Colorectal Neoplasms, Treatment Outcome, Disease-Free Survival, Angiogenesis Inhibitors, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
